Navigation Links
Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
Date:8/21/2012

SAN DIEGO, Aug. 21, 2012 /PRNewswire/ -- Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today that it has initiated a first-of-its-kind, large-scale prospective clinical outcomes study of its pharmacogenetic test. The study, which will encompass more than 30 practice sites nationally, is designed to evaluate the relationship between CYP genotype, as determined by Millennium Pharmacogenetic Testing (PGT), and clinical outcomes including level of analgesia, functional status, and clinically significant opioid-related adverse events. The study will also seek to assess the benefit to prescribers of pharmacogenetic information arising from Millennium PGT, and characterize any corresponding changes in prescribing patterns.

(Logo:  http://photos.prnewswire.com/prnh/20120516/LA07836LOGO)

"Our company's commitment to furthering the science and field of pain management includes providing research that supports best practices," said Howard Appel, President of Millennium Laboratories. "To that end, this study will seek to expand and improve an understanding of how genetic variability affects response to prescribed medications to help improve medication choices and efficacy, and minimize side effects – potentially resulting in improved patient care."  

"Pharmacogenetic testing can provide valuable information through the detection of genetic variations in enzymes associated with the metabolism of medications commonly prescribed to patients suffering from debilitating chronic pain and pain-related effects. Utilized in combination with urine drug testing, it offers significant potential to improve the safety and efficacy of drug treatment and reduce adverse effects among certain patients," said Michael Brennan, M.D., a nationally recognized pain specialist practicing in Fairfield, Connecticut. "Ongoing research such as the major study announced today by Millennium will be critical in helping to facilitate a better understanding of the important role this new tool can play in pain management."

The largest study of its kind, up to 1,250 subjects meeting the study entry criteria will be enrolled into the initial, cross-sectional phase. Subjects categorized by the test as poor or ultra-rapid metabolizers will continue into the longitudinal phase of the study.

About Millennium Pharmacogenetic Testing

Millennium PGT saliva-based testing detects genetic variations in enzymes associated with the metabolism of medications commonly prescribed to patients suffering from debilitating chronic pain and related symptoms. Designed to serve as an objective tool to support individualized therapy, the test will help clinicians identify patients who may benefit from modifying the drug selection or dosing of certain prescribed opioids including methadone, benzodiazepines, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs).

About Millennium Laboratories

Millennium Laboratories (http://millenniumlabs.com/) is the leading research-based, clinical diagnostic company dedicated to improving the lives of people with chronic pain. The company provides healthcare professionals with medication monitoring, drug detection and pharmacogenetic testing services to personalize treatment plans to improve clinical outcomes and patient safety.

Millennium's commitment to advancing the science of pain management includes a strong focus on industry research, education and advocacy. Through its association with the Millennium Research Institute, a nonprofit national research center, it has gained respect as a leader in providing healthcare professionals with education and research to advance the assessment and management of chronic pain.


'/>"/>
SOURCE Millennium Laboratories
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
2. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
3. Millennium Surgical Corp. Announces Sales Figures, Growth
4. Millennium Surgical Corp. Develops Online Sterilization Resource Center
5. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
6. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
7. SpineMark Corporation Partners with PhDx and Millennium Environmental to Create an ISO type Spine Protocol Management System
8. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as SVP Operations
9. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
10. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
11. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... ALTO, Calif. , Dec. 7, 2016  Varian ... an update to its previously announced plans to separate ... be executed via a tax-free distribution to Varian stockholders ... stand-alone public company that will hold the Imaging Components ... expected to be executed by the end of January ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer ... trial in patients with unresectable malignant pleural mesothelioma ... (PFS). The data, presented at the 17 th ... Vienna , showed nintedanib plus ... placebo plus pemetrexed/cisplatin, with a significantly improved PFS ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... ... A quote from Dr. Edward Hallowell, host of CRN International’s “Distraction” podcast ... glimpse into the mind of those people with ADHD. , Dr. Hallowell, a child ... people with ADHD as having “Ferrari engines for a brain, with bicycle brakes.” , ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff ... located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, ... treatment for a brain tumor. , Jason Bauer and his family are longtime ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm ... Boroughs, is launching a charity drive to raise funds that will benefit the Marine ... of marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry ... through user experience. , BOC Global Events & Training Group is a professional ...
Breaking Medicine News(10 mins):